CEDAR KNOLLS, N.J.,
Sept. 26, 2018 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS),
a biotherapeutics and bionutrition company and the owner of
Fortetropin®, a proprietary bioactive composition
derived from fertilized egg yolk that helps build lean muscle,
announced today that MYOS will exhibit at the Atlantic Coast
Veterinary Conference in Atlantic
City, NJ, from October 8-11, 2018. Featured at
the event will be MYOS Canine Muscle Formula™ our first
Fortetropin®-based veterinary product.
For 29 years, the Atlantic Coast Veterinary Conference (ACVC)
has been providing veterinary healthcare professionals with
unmatched continuing education and networking opportunities.
This year, ACVC will be proudly presented by American
Veterinarian®– the premier news and
information resource for the veterinary
profession. Please visit Booth #624 to learn
about Fortetropin's benefits for aging dogs who are experiencing
muscle loss, or go to www.myospet.com.
Fortetropin® has been clinically
shown to increase lean muscle size and mass in humans and addresses
muscle loss and supports muscle health in dogs.
Fortetropin is a unique bioactive composition derived from
fertilized egg yolk and is manufactured using a patented technology
in order to retain its nutrient-dense nature and biological
integrity and bioactivity. Attendees will also be able to
purchase MYOS Canine Muscle Formula at specially
discounted conference prices.
Joseph Mannello, Chief Executive
Officer of MYOS, commented, "The ACVC is attended by over 2,000
people in the veterinary and animal health fields.
American Veterinarian, the show's sponsor, expresses that
its 'mission is to provide a broader view of medicine that
encompasses the intertwined worlds of science, medicine, and
health'. We look forward to the opportunity to connect with
veterinary professionals at this conference, educating and
providing greater awareness of the benefits of Fortetropin in our
MYOS Canine Muscle Formula."
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company™", is a Cedar Knolls, NJ-based bionutrition company
that develops and markets products that improve muscle health and
performance. MYOS is the owner of Fortetropin®, a fertilized egg
yolk-based product manufactured via a proprietary process to retain
and optimize its biological activity. Fortetropin has been
clinically shown to increase muscle size and lean body mass in
conjunction with resistance training. MYOS believes Fortetropin has
the potential to redefine existing standards of physical health and
wellness. For more information, please visit www.MYOSRENS.com.
Forward-Looking Statements
Any statements
in this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including our Qurr®, Yolked®, and MYOS Canine
Muscle Formula™ products, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter into
new partnership opportunities and the success of our existing
partnerships, the ability to generate the forecasted revenue stream
and cash flow from sales of our products, the ability to continue
increasing our revenue and gross profit margins, the ability to
achieve a sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after
the date on which such statement is made except as required by
law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
SOURCE MYOS RENS Technology Inc.